准ACSLs来调节铁和癌症免疫力
Junhong Lin1, Yongfeng Lai2, Fujia Lu1
1Department of Immunology, School of Basic Medicine, Tongji Medical College and State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Huazhong University of Science and Technology, Wuhan, China.
Trends in endocrinology and metabolism: TEM
|October 18, 2024
概括
长链乙-A合成酶家族成员 (ACSLs) 调节癌症的进展和细胞死亡. 向ACSLs,特别是ferroptosis中的ACSL4,为新型癌症免疫疗法提供了潜力.
科学领域:
- 生物化学 生物化学
- 癌症生物学 癌症生物学
- 免疫学 免疫学 免疫学
背景情况:
- 五个长链乙-CoA合成酶家族成员 (ACSLs) 催化长链脂肪酸 (LCFA) 转化为LCFA-乙-CoA进行代谢.
- ACSLs对于脂肪酸氧化,脂质合成和蛋白质酸化至关重要.
研究的目的:
- 本次审查重点关注ACSL及其LCFA基质.
- 它探讨了ACSLs在调节癌症扩散,转移和治疗耐药性的作用.
- 该综述检查了ACSL参与铁和抗瘤免疫反应.
主要方法:
- 在癌症中ACSL功能的文献综述.
- 分析ACSL在铁和脂质过氧化中的作用.
- 讨论ACSL对抗瘤免疫力的影响.
主要成果:
- ACSL在癌症扩散,转移和治疗耐药性方面发挥着重要作用.
- ACSL4被确定为铁亡的关键调节者,这是免疫细胞死亡的一种形式.
- ACSLs影响对铁亡的敏感性,并调节抗瘤免疫反应.
结论:
- 准ACSL是一种有前途的癌症治疗策略.
- 对免疫细胞中ACSL功能的进一步研究是必要的,以提高免疫疗法的疗效.
- 了解ACSL介导的途径可以导致增强癌症免疫疗法的新方法.
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Regulation of Hematopoietic Stem Cells
3.1K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.1K


